PRA Health Sciences Inc (PRAH) Receives Average Recommendation of “Buy” from Analysts

Share on StockTwits

PRA Health Sciences Inc (NASDAQ:PRAH) has received an average rating of “Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $98.45.

Several equities research analysts recently commented on the company. Jefferies Financial Group restated a “buy” rating and set a $115.00 target price on shares of PRA Health Sciences in a research report on Friday, July 20th. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 16th. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research report on Tuesday, July 3rd. Finally, ValuEngine upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 12th.

Shares of PRA Health Sciences traded down $0.78, hitting $106.92, on Friday, Marketbeat Ratings reports. 542,261 shares of the company’s stock traded hands, compared to its average volume of 583,596. PRA Health Sciences has a one year low of $73.05 and a one year high of $108.02. The company has a debt-to-equity ratio of 1.29, a current ratio of 0.83 and a quick ratio of 0.83. The firm has a market cap of $6.85 billion, a price-to-earnings ratio of 33.41, a PEG ratio of 1.65 and a beta of 0.49.

A number of large investors have recently made changes to their positions in PRAH. Advisor Group Inc. boosted its holdings in PRA Health Sciences by 403.6% in the fourth quarter. Advisor Group Inc. now owns 5,384 shares of the medical research company’s stock worth $490,000 after acquiring an additional 4,315 shares in the last quarter. Stone Ridge Asset Management LLC bought a new position in PRA Health Sciences in the fourth quarter worth approximately $211,000. Raymond James & Associates boosted its holdings in PRA Health Sciences by 56.4% in the fourth quarter. Raymond James & Associates now owns 21,318 shares of the medical research company’s stock worth $1,941,000 after acquiring an additional 7,684 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in PRA Health Sciences by 11.0% in the fourth quarter. TIAA CREF Investment Management LLC now owns 254,021 shares of the medical research company’s stock worth $23,134,000 after acquiring an additional 25,177 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its holdings in PRA Health Sciences by 52.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,647 shares of the medical research company’s stock worth $150,000 after acquiring an additional 567 shares in the last quarter. Institutional investors and hedge funds own 98.88% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Understanding Analyst Recommendations

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply